Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of “Buy” from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been assigned an average rating of “Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $64.17.

A number of equities research analysts have recently weighed in on JSPR shares. Royal Bank of Canada initiated coverage on Jasper Therapeutics in a research note on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price objective for the company. TD Cowen started coverage on Jasper Therapeutics in a research report on Monday, March 18th. They issued an “outperform” rating for the company. Oppenheimer reissued an “outperform” rating and set a $80.00 price target on shares of Jasper Therapeutics in a research report on Thursday, March 7th. Finally, Evercore ISI started coverage on shares of Jasper Therapeutics in a report on Wednesday, April 3rd. They issued an “outperform” rating and a $65.00 price objective for the company.

Jasper Therapeutics Price Performance

Shares of JSPR opened at $21.18 on Friday. The firm has a 50-day simple moving average of $24.91 and a two-hundred day simple moving average of $14.08. The stock has a market cap of $318.97 million, a PE ratio of -3.42 and a beta of 2.22. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. As a group, sell-side analysts expect that Jasper Therapeutics will post -5 earnings per share for the current fiscal year.

Insider Buying and Selling at Jasper Therapeutics

In other news, major shareholder Velan Capital Investment Manag bought 350,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $4,532,500.00. Following the completion of the purchase, the insider now owns 1,188,500 shares of the company’s stock, valued at $15,391,075. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 3.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. Opaleye Management Inc. acquired a new stake in Jasper Therapeutics in the fourth quarter valued at $3,144,000. Kingdon Capital Management L.L.C. increased its holdings in shares of Jasper Therapeutics by 16.4% in the 4th quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after acquiring an additional 500,000 shares during the last quarter. Fernwood Investment Management LLC raised its position in shares of Jasper Therapeutics by 8.8% during the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after acquiring an additional 40,000 shares in the last quarter. Monaco Asset Management SAM purchased a new stake in Jasper Therapeutics during the fourth quarter worth approximately $197,000. Finally, Cowen AND Company LLC acquired a new position in Jasper Therapeutics in the third quarter valued at approximately $140,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.